Jarod Marcotte
Physician Assistant · Leavenworth, KSNPI 1093783599
Payments from drug & device makers
Across 660 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$981
- AstraZeneca$931
- Novo Nordisk$708
- Pfizer$601
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$546
- plus $5K from 44 others
What the payments were for
- Speaking & faculty fees$8257%
- Food & beverage$10,47792%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,397 in reported general payments places this provider in the 95th percentile of 1,016 physician assistant providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 70 | $71,468 |
| JardianceEmpagliflozin | 63 | $64,776 |
| EliquisApixaban | 68 | $61,448 |
| LinzessLinaclotide | 60 | $36,231 |
| FarxigaDapagliflozin Propanediol | 46 | $33,406 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $32,742 |
| MounjaroTirzepatide | 23 | $24,754 |
| XareltoRivaroxaban | 19 | $23,858 |
| TrulicityDulaglutide | 20 | $23,710 |
| VraylarCariprazine Hcl | 12 | $20,116 |
| JanuviaSitagliptin Phosphate | 19 | $16,922 |
| RexultiBrexpiprazole | 12 | $16,760 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $13,271 |
| GemtesaVibegron | 13 | $9,920 |
| Dexlansoprazole DrDexlansoprazole | 34 | $8,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $708 | $71,46870 claims |
| Boehringer IngelheimJardiance | $247 | $64,77663 claims |
| PfizerEliquis | $601 | $61,44868 claims |
| AbbVieLinzess, Vraylar | $2,304 | $56,34872 claims |
| Lilly USA, LLCMounjaro, Trulicity | $981 | $48,46543 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $318 | $46,01270 claims |
| AstraZenecaFarxiga | $931 | $33,40646 claims |
| Johnson & JohnsonXarelto | $100 | $23,85819 claims |
| MerckJanuvia | $266 | $16,92219 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $370 | $16,76012 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $50 | $9,92013 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Amitiza | $211 | $5,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in Leavenworth
- Charles GlassLeavenworth$11K
- Angela ReschLeavenworth$10K
- Sierra FergusonWichita$25K
- Dylan TimmermannTopeka$19K
- Heather HowellKansas City$16K
- Amy BrettmanShawnee$14K
- Ashton YoungersWichita$14K
- Anthony GunawanLakin$13K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.